v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Product Information [Line Items]        
Net loss $ 36,456,347 $ 1,512,267    
Net cash used in operating activities 1,776,349 1,494,792    
Accumulated deficit 99,303,616   $ 62,807,817  
Stockholder's equity 44,302,919 4,865,914 6,801,055 $ 4,945,362
Working capital deficit 44,998,742      
Contract liabilities, revenue recognized 3,500 22,250    
Uncompleted contract liabilities, revenue recognized $ 3,500      
Research and development transaction term The transaction term is for 5-years, starting in September 2021      
Cash FDIC insured amount $ 898,012   186,466  
Revenue 55,295 78,975    
Accounts receivable 48,295   32,125  
Deferred revenue 177,050   $ 156,550  
Patient reporting and contract research expense 0 113,295    
Uncertain tax positions 0 0    
Income tax, interest and penalties $ 0 $ 0    
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member]        
Product Information [Line Items]        
Concentration risk, percentage 72.00% 56.00%    
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member]        
Product Information [Line Items]        
Concentration risk, percentage   35.00%    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]        
Product Information [Line Items]        
Concentration risk, percentage 82.00%   59.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]        
Product Information [Line Items]        
Concentration risk, percentage     41.00%  
Customer Concentration Risk [Member] | Deferred Revenue [Member] | Customer One [Member]        
Product Information [Line Items]        
Concentration risk, percentage 73.00%   65.00%  
Customer Concentration Risk [Member] | Deferred Revenue [Member] | Customer Two [Member]        
Product Information [Line Items]        
Concentration risk, percentage 21.00%   24.00%  
General and Administrative Expense [Member]        
Product Information [Line Items]        
Research and development expense $ 50,000 $ 25,000    
Minimum [Member]        
Product Information [Line Items]        
Property and equipment, estimated useful lives 3 years      
Maximum [Member]        
Product Information [Line Items]        
Property and equipment, estimated useful lives 5 years      
Cash FDIC insured amount $ 250,000